2-Deoxy-2,2-difluoro-D-erythro-pentafuranous-1-ulose-3,5-dibenzoate

We are 2-Deoxy-2,2-difluoro-D-erythro-pentafuranous-1-ulose-3,5-dibenzoate CAS:122111-01-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:
2-Deoxy-2,2-difluoro-D-erythro-pentafuranous-1-ulose-3,5-dibenzoate
CAS.NO:122111-01-7
Synonyms:
((2R,3R)-3-(Benzoyloxy)-4,4-difluoro-5-oxotetrahydrofuran-2-yl)methyl benzoate
2-Deoxy-2,2-Difluoro-d-Erythro-Pentofuranos-1-Ulose-3,5-Dibenzoate
[(2R,3R)-3-benzoyloxy-4,4-difluoro-5-oxooxolan-2-yl]methyl benzoate 
2-Deoxy-2,2-difluoro-D-erythro-pentonic acid γ-Lactone 3,5-dibenzoate
Molecular Formula:C19H14F2O6
Molecular Weight:376.30800
 
Physical and Chemical Properties:
Density:1.41
Melting point:117-119ºC
Boiling point:437.2ºC
Flash point:210.5ºC
Index of Refraction:1.57
 
Specification:
Appearance:White to off-white crystalline powder
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Gemcitabine intermediate

2-Deoxy-2,2-difluoro-D-erythro-pentafuranous-1-ulose-3,5-dibenzoate


Related News: Active pharmaceutical ingredients directly impact disease.1-naphthol CAS:90-15-3 High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies.51800-19-2 As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.3-Heptylacrolein Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.

Related Products
Product Name
3-Bromotoluene View Details
cis-2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethyl methanesulphonate View Details
Dimethyl adipate View Details
Terlipressin Acetate manufacturer 4,6-dibromothieno[3,4-c]furan-1,3-dione manufacturer 4-Aminobenzotrifluoride manufacturer N,N,N-Trimethyl-1-ammonium adamantane manufacturer chlorotrimethylsilane manufacturer